Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.46 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.46 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.46 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991140 | 0.86 | CSNK2A1 (0.53) | CSNK2A1TAAR1KDM4EATMHTR7 | |
| SCHEMBL3574310 | 0.84 | CTSA (0.50) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL11672601 | 0.84 | CYP1A2 (0.47) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL24093214 | 0.83 | CYP1A1 (0.46) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL3573143 | 0.83 | TTR (0.59) | CSNK2A1CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL7229895 | 0.83 | CYP1A1 (0.46) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL27815745 | 0.83 | CYP1A1 (0.46) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL2806289 | 0.82 | CSNK2A1 (0.54) | CSNK2A1TAAR1ALDH1A1HPGD | |
| SCHEMBL20782113 | 0.80 | HTR7 (0.66) | TAAR1CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL20781813 | 0.80 | CYP1A1 (0.44) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2017-10-19 | — | — | US | disclosed |
| US-9586963-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | GENFIT (FR) | 2017-03-07 | — | — | US | disclosed |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | GENFIT (FR) | 2015-02-05 | — | — | US | disclosed |
| EP-1698635-B1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-12-14 | — | — | EP | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7547680-B2 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICALS, CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1698635-A1 | BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | CSNK2A1 3651/4885TAAR1 2821/4885CYP1A1 941/4885 |
| US-20080038242-A1 | Benzimidazole derivatives and medical uses thereof | SLCO1B3, SLCO2A1, SLCO2B1 | CSNK2A1 4228/4885TAAR1 2914/4885CYP1A1 761/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | CSNK2A1 3567/4885TAAR1 2908/4885CYP1A1 778/4885 |
| US-10799510-B2 | Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists | NR1D1, NR1D2, PER2 | CSNK2A1 255/4885TAAR1 285/4885CYP1A1 130/4885 |
| US-20170296548-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | CSNK2A1 255/4885TAAR1 285/4885CYP1A1 130/4885 |
| US-20150038503-A1 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS | NR1D1, NR1D2, PER2 | CSNK2A1 255/4885TAAR1 285/4885CYP1A1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.